Molecular Partners completes manufacturing runs in bid for Covid-19 drug

Molecular Partners said that it had completed initial manufacturing runs for its candidate MP0420 that it aims to test in humans starting in November

ZURICH (Reuters) - Switzerland's Molecular Partners, which is hoping to produce an antiviral drug against COVID-19, said on Monday that it had completed initial manufacturing runs for its candidate MP0420 that it aims to test in humans starting in November.

"It is essential to demonstrate the ability to manufacture and deploy these medicines," said Chief Executive Patrick Amstutz.

(Reporting by John Miller; editing by Thomas Seythal)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)